Slovakia's audit office reports potential conflicts of interest in state drug policy to prosecutor

Slovakia's Supreme Audit Office has sent findings about potential conflicts of interest and irregularities in the country's pharmaceutical policy to Prosecutor General Maroš Žilinka. The audit office documented possible conflicts of interest and negotiations with pharmaceutical companies that were conducted without proper records. The Supreme Audit Office, which oversees government spending and operations, identified these irregularities as part of its review of how Slovakia manages its drug policy. The findings suggest problems in how state officials have handled relationships with pharmaceutical firms, raising questions about transparency in decisions affecting public health spending and drug accessibility.